Tag Archives: Corbus Pharmaceuticals

Oppenheimer Believes Corbus Pharmaceuticals (NASDAQ: CRBP) Won’t Stop Here

Oppenheimer analyst Leland Gershell assigned a Buy rating to Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $28.00. The company’s shares closed last Monday at $8.14, close to its 52-week high of $8.66. According to

Corbus Pharmaceuticals (CRBP) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $28.00. The company’s shares closed last Thursday at $7.97, close to its 52-week high of $8.66. According to

Corbus Pharmaceuticals (CRBP) Receives a Buy from Nomura

Nomura analyst Christopher Marai maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $12.00. The company’s shares closed last Wednesday at $6.46. According to TipRanks.com, Marai is a 4-star analyst with

Oppenheimer Gives a Buy Rating to Corbus Pharmaceuticals (CRBP)

Oppenheimer analyst Leland Gershell assigned a Buy rating to Corbus Pharmaceuticals (CRBP – Research Report) yesterday and set a price target of $28.00. The company’s shares closed last Monday at $6.64. According to TipRanks.com, Gershell is a 5-star analyst with

Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital

In a report issued on August 8, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), with a price target of $23. The company’s shares closed on Friday at $5.88. According to TipRanks.com,

Corbus Pharmaceuticals (CRBP) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price target of $24. The company’s shares closed yesterday at $6.94. Fein commented: “Valuation and risks to our investment thesis.